UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

SCHEDULE 14C

INFORMATION REQUIRED IN INFORMATION STATEMENT

SCHEDULE 14C INFORMATION

Information Statement Pursuant to Section 14(c) of
the Securities Exchange Act of 1934 (Amendment No. )

Check the appropriate box:

[X] Preliminary Information Statement [ ] Confidential, for use of the
Commission only (as permitted by
Rule 14c-5(d)(2))
[ ] Definitive Proxy Statement

MACROCHEM CORPORATION
(Name of Registrant as Specified in Its charter)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14c-5(g) and 0-11.

(1) Title of each class of securities to which transaction applies:

- -------------------------------------------------------------------------------

(2) Aggregate number of securities to which transaction applies:

- -------------------------------------------------------------------------------

(3) Per unit price or other underlying value of transaction computed pursuant
to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is
calculated and state how it was determined):

- -------------------------------------------------------------------------------

(4) Proposed maximum aggregate value of transaction:

- -------------------------------------------------------------------------------

(5) Total fee paid:

- -------------------------------------------------------------------------------

[ ] Fee paid previously with preliminary materials:

[ ] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.

(1) Amount Previously Paid:

- -------------------------------------------------------------------------------

(2) Form, Schedule or Registration Statement No.:

- -------------------------------------------------------------------------------

(3) Filing Party:

- -------------------------------------------------------------------------------

(4) Date Filed:

- -------------------------------------------------------------------------------

MACROCHEM CORPORATION
110 HARTWELL AVENUE
LEXINGTON, MASSACHUSETTS 02421

INFORMATION STATEMENT
DATED JANUARY [ ], 2006

_______________________________

THIS IS NOT A NOTICE OF A SPECIAL MEETING OF SHAREHOLDERS AND NO
SHAREHOLDER MEETING WILL BE HELD TO CONSIDER ANY MATTER DESCRIBED HEREIN. WE ARE
NOT ASKING YOU FOR A PROXY AND YOU ARE REQUESTED NOT TO SEND US A PROXY.

_______________________________

This Information Statement is being furnished to all holders of record of
the common stock, par value $0.01 per share, of MacroChem Corporation
("MacroChem", the "Company", "we", "us" or "our") and Series C Cumulative
Convertible Preferred Stock, par value $0.01 per share, of MacroChem (the
"Series C Preferred Stock") at the close of business on January 5, 2006. Unless
otherwise indicated, all references in this Information Statement to common
stock share numbers and per-share prices of common stock reflect the 1 for 7
reverse stock split of the Company's common stock, which was effective as of
December 30, 2005.

The Series C Preferred Stock is convertible into shares of common stock and
votes together with the common stock on an as-if-converted to common stock
basis. The Certificate of Designations, Rights and Preferences of the Series C
Preferred Stock (the "Certificate of Designation") contains a provision that
restricts a holder of Series C Preferred Stock from (i) converting Series C
Preferred Stock into common stock to the extent that such conversion would
result in the holder owning more than 4.95% of the issued and outstanding common
stock of the Company or (ii) voting together with the common stock on an
as-if-converted to common stock basis in respect of more than 4.95% of the
issued and outstanding common stock of the Company (the "Beneficial Ownership
Cap"). The Certificate of Designation also provides, however, that a holder of
Series C Preferred Stock may elect, subject to certain conditions, to be exempt
from the Beneficial Ownership Cap. On January 3, 2006, there were 250 shares of
Series C Preferred Stock issued and outstanding, 200 of which were issued to SCO
Capital Partners LLC and the remaining 50 of which were issued to Lake End
Capital LLC. The 200 shares of Series C Preferred Stock held by SCO Capital
Partners LLC, which has elected to be exempt from the Beneficial Ownership Cap,
were convertible into an aggregate of 11,428,571 shares of common stock. The 50
shares of Series C Preferred Stock issued to Lake End Capital LLC, which is
subject to the Beneficial Ownership Cap, were convertible into 311,616 shares of
common stock. As a result, on January 3, 2006, the Series C Preferred Stock was
convertible into an aggregate of 11,724,762 shares of common stock. Together
with the 5,983,670 shares of common stock outstanding on January 3, 2006, the
total number of shares eligible to vote or consent to a matter (on an
as-if-converted to Common Stock basis) is 17,708,432, which amount is referred
to in this Information Statement as the "Voting Securities." Each share of
common stock (including the shares of common stock into which the Series C
Preferred Stock is convertible) entitles the holder to one vote with respect to

the matters discussed in this Information Statement. Other than the common stock
and the Series C Preferred Stock, the Company has no other Voting Securities.

This Information Statement advises shareholders that the Board adopted
resolutions on December 23, 2005:

o To authorize an amendment to the Company's certificate of
incorporation to effect a reverse stock split of the Company's
common stock, pursuant to which any six shares of issued and
outstanding common stock on the date of the filing of the
amendment to the Company's certificate of incorporation would
be combined into one share of common stock and to authorize
the Company's Board of Directors to file such amendment with
the Secretary of State of the State of Delaware.

This Information Statement further advises shareholders that the
above-mentioned action was approved by written consent by the holders of the
Series C Preferred Stock, who hold approximately 66.2% of the outstanding Voting
Securities (the "Principal Stockholders").

The action described above will not become effective until the filing with
the Secretary of State of the State of Delaware of the amendment to the
Company's certificate of incorporation, which will not occur before the date
that is twenty (20) days from the date of the mailing of this Information
Statement.

This Information Statement is first being provided to the stockholders on
or about January [ ], 2006.

REQUIRED CONSENT

Consistent with Delaware law and under the Company's bylaws, stockholder
approval of an action may be taken by written consent of the holders of
outstanding stock having not less than the minimum number of votes that would be
necessary to authorize or take the action at a meeting at which all shares
entitled to vote thereon were present and voted. Under Delaware law, the
affirmative vote of a majority of the outstanding shares of the Company's voting
stock is required to approve an amendment to the Company's certificate of
incorporation, as amended.

RECENT PRIVATE PLACEMENT - CHANGE OF CONTROL

On December 23, 2005, we entered into a Preferred Stock and Warrant
Purchase Agreement (the "Purchase Agreement") with SCO Capital Partners LLC and
Lake End Capital LLC (the "Purchasers"). Pursuant to the terms of the Purchase
Agreement, we issued 250 shares of our Series C Cumulative Convertible Preferred
Stock (the "Series C Preferred Stock") and six-year warrants (the "Warrants") to
purchase 14,285,714 shares of the Company's common stock at an exercise price of
$0.21 per share, for an aggregate purchase price of $2.5 million. The Warrants
contain an exercise restriction similar to the Beneficial Ownership Cap
restriction of the Series C Preferred Stock, such that the right of a holder to
exercise a warrant is restricted to the extent that it would cause the holder to
beneficially own more than 4.95% of the issued and outstanding common stock of
the Company. SCO Capital Partners LLC has elected to be exempt from this

restriction, but Lake End Capital LLC has not. The Purchasers funded the
aggregate purchase price from their cash reserves.

The terms and provisions of the Series C Preferred Stock are set forth in
the Certificate of Designations, Rights and Preferences of Series C Cumulative
Convertible Preferred Stock, a copy of which is attached as an exhibit to the
Company's Current Report on Form 8-K dated as of December 27, 2005. The Series C
Preferred Stock has a liquidation value of $10,000 per share, is entitled to a
dividend of 10% per annum, payable in shares of our common stock at our option,
which dividend rate is subject to increase to 14% upon the occurrence of certain
events. The number of shares of common stock into which each share of Series C
Convertible Preferred Stock is convertible is determined by dividing the
liquidation value per share plus all accrued and unpaid dividends thereon by
$0.175. As of January 3, 2006, the Series C Preferred Stock acquired by the
Purchasers is convertible into 11,740,187 shares of common stock. The holders of
the Series C Preferred Stock vote on an as-converted basis with the holders of
our common stock (subject to the Beneficial Ownership Cap applicable to Lake End
Capital LLC), and therefore hold approximately 66.2% of the voting power of our
outstanding securities. Assuming both the conversion of the Series C Preferred
Stock and the exercise of all of the warrants acquired by the Purchasers
(subject to the Beneficial Ownership Cap applicable to Lake End Capital LLC),
the Purchasers would hold approximately 80% of the outstanding common stock of
the Company. Consequently, the Purchasers have acquired control of the Company.

In addition, pursuant to the terms of the Purchase Agreement, we agreed to
effect a 1 for 6 reverse split of our common stock as promptly as practicable in
addition to the 1 for 7 reverse split of our common stock which we effected as
of December 30, 2005. As noted above, the Purchasers have submitted written
consents approving this 1 for 6 stock split, which is expected to become
effective 20 days after we send this information statement to our stockholders.

The Purchase Agreement also provides that, for as long as at least 20% of
the shares of Series C Preferred Stock issued thereunder remain outstanding, SCO
Capital Partners LLC has the right to designate two individuals to serve on our
board of directors (the "SCO Director Designees"). On December 28, 2005, SCO
Capital Partners LLC informed MacroChem that the initial SCO Director Designees
shall be Jeffrey B. Davis and Howard S. Fischer. The Purchase Agreement
prohibits us from taking certain actions without the approval of a majority of
our board of directors, which majority must include at least one of the SCO
Director Designees, until we have received gross proceeds of at least $3.5
million from additional closings under the Purchase Agreement, as described
below, or March 31, 2006, whichever occurs first. There can be no assurance that
there will be any additional closings under the Purchase Agreement or that we
will be able to raise any additional capital. Until we are able to raise
additional capital, if at all, our operations will be significantly limited.

SCO Securities LLC, an affiliate of SCO Capital Partners LLC, acted as
placement agent in connection with the private placement. For its services as
placement agent, we paid SCO Securities LLC a fee equal to 7% of the gross
proceeds, or $175,000, and issued a six-year warrant to purchase 1,428,571
shares of our common stock at an exercise price of $0.175 per share. The terms
of the warrant issued to the placement agent are the same as the terms of the
warrants issued to the Purchasers except that the exercise price of the warrant

issued to the placement agent is $0.175. On December 28, 2005, SCO Securities
LLC assigned its warrant to the following four persons in the amounts listed:
(i) warrant to purchase 857,143 shares of common stock to SCO Capital Partners
LLC; (ii) warrant to purchase 285,714 shares of common stock to Lake End Capital
LLC, (iii) warrant to purchase 142,857 shares of common stock to Mark Alvino and
(iv) warrant to purchase 142,857 shares of common stock to Howard Fischer. We
also paid SCO Securities LLC $25,000 for out-of-pocket expenses incurred in
connection with the transaction and agreed to pay all reasonable expenses of the
Purchasers incurred in connection with the private placement.

The securities offered and sold to the Purchasers in the private placement
have not been registered under the Securities Act of 1933, as amended (the
"Securities Act") and were sold in reliance upon the exemption from securities
registration afforded by Regulation D under the Securities Act. All of the
Purchasers represented to MacroChem that they were "accredited investors", as
defined in Rule 501 of Regulation D. In connection with the private placement,
MacroChem entered into an Investor Rights Agreement with the Purchasers,
pursuant to which MacroChem is required to file a registration statement with
the Securities and Exchange Commission covering the resale of the common stock
issuable upon conversion of the Series C Preferred Stock, issuable as payment of
dividends on the Series C Preferred Stock and issuable upon exercise of the
Warrants and the warrants issued to the placement agent.

The above summary is not intended to be complete and is qualified in its
entirety by reference to the detailed provisions in the agreements which are
attached as exhibits to our Current Report on Form 8-K filed on December 27,
2005, which is incorporated herein by reference.

AMENDMENT TO
CERTIFICATE OF INCORPORATION TO EFFECT A REVERSE STOCK SPLIT

OVERVIEW

The Board of Directors of the Company (the "Board") has unanimously
approved an amendment to the Company's certificate of incorporation to effect a
reverse stock split of all outstanding shares of the Company's Common Stock at
an exchange ratio of one-to-six. The text of the form of amendment to the
Company's certificate of incorporation is attached to this information statement
as Appendix A. In addition, the Board has determined that effecting such a
reverse split is in the best interests of MacroChem and its stockholders, and
the holders of the Series C Preferred Stock holding approximately 66.2% of the
outstanding Voting Securities have duly approved the one-for-six reverse stock
split. The reverse stock split will become effective upon the filing of the
amendment to the Company's certificate of incorporation with the Secretary of
State of the State of Delaware, which will not occur before the date that is
twenty (20) days from the date of the mailing of this Information Statement.

As a result of the one for six reverse stock split, each six shares of
outstanding Common Stock will be exchanged for one new share of Common Stock.
Except for adjustments that may result from the treatment of fractional shares
as described below, each stockholder will hold the same percentage of
outstanding Common Stock immediately following the reverse stock split as such
stockholder held immediately prior to the reverse stock split. Currently,
MacroChem is authorized to issue up to a total of 106,000,000 shares of capital
stock, consisting of 6,000,000 shares of Preferred Stock and 100,000,000 shares
of Common Stock. This amendment will not change the number of total authorized
shares of our capital stock. Thus, immediately following the reverse stock
split, the total number of authorized shares of capital stock will remain at
106,000,000, consisting of 6,000,000 shares of Preferred Stock and 100,000,000
shares of Common Stock. The par value of the Preferred Stock and Common Stock
will remain unchanged at $0.01 per share.

In addition to the 5,983,670 shares of Common Stock outstanding at January
3, 2006, the Board has reserved up to approximately 94,016,330 shares of Common
Stock which may be issued upon conversion of other classes of securities,
including subsequently issued shares of Series C Preferred Stock, exercise of
warrants, options and rights, including options and rights granted under the
Company's stock option plans. Except with respect to the shares of common stock
issuable upon conversion of the Series C Preferred Stock at the request of the
holder thereof, issuable in payment of dividends on the Series C Preferred
Stock, or issuable upon the exercise, at the option of the holder, of any
outstanding options or warrants, or in connection with equity financing
activities, at present the Board has no other commitment to issue the additional
shares of Common Stock.

REASONS FOR THE REVERSE STOCK SPLIT

The Board believes that the increased market price of the Common Stock
expected as a result of implementing the reverse stock split will improve the
marketability and liquidity of the Common Stock and will encourage interest and

trading in the Common Stock. Because of the trading volatility often associated
with low-priced stocks, many brokerage houses and institutional investors have
internal policies and practices that either prohibit them from investing in
low-priced stocks or tend to discourage individual brokers from recommending
low-priced stocks to their customers. Some of those policies and practices may
function to make the processing of trades in low-priced stocks economically
unattractive to brokers. Additionally, because brokers' commissions on
low-priced stocks generally represent a higher percentage of the stock price
than commissions on higher-priced stocks, the current average price per share of
the Common Stock can result in individual stockholders paying transaction costs
representing a higher percentage of their total share value than would be the
case if the share price were substantially higher. It should be noted that the
liquidity of the Common Stock may be adversely affected by the reverse split
given the reduced number of shares that would be outstanding after the reverse
stock split. The Board anticipates, however, that the expected higher market
price will reduce, to some extent, the negative effects on the liquidity and
marketability of the Common Stock inherent in some of the policies and practices
of institutional investors and brokerage houses described above.

The Board does not intend for this transaction to be the first step in a
series of plans or proposals of a "going private transaction" within the meaning
of Rule 13e-3 of the Securities Exchange Act of 1934, as amended.

The Board has determined that the reverse stock split is in the best
interests of MacroChem and its stockholders. Such determination was based upon
certain factors, including existing and expected marketability and liquidity of
the Common Stock, prevailing market conditions and the likely effect on the
market price of the Common Stock.

EFFECTS OF THE REVERSE STOCK SPLIT

After the effective date of the reverse stock split, each stockholder will
own a reduced number of shares of the Common Stock. However, the reverse stock
split will affect all of the Company's stockholders uniformly and will not
affect any stockholder's percentage ownership interests, except to the extent
that the reverse split results in any of the stockholders owning a fractional
share as described below. Proportionate voting rights and other rights and
preferences of the holders of Common Stock will not be affected by the reverse
stock split (other than as a result of the payment of cash in lieu of fractional
shares). For example, a holder of 2% of the voting power of the outstanding
shares of Common Stock immediately prior to the reverse stock split would
continue to hold 2% of the voting power of the outstanding shares of Common
Stock immediately after the reverse stock split. The number of stockholders of
record will not be affected by the reverse stock split (except to the extent
that any stockholder holds only a fractional share interest and receives cash
for such interest after the reverse stock split).

The approximate number of shares of our Common Stock that will be
outstanding as a result of the reverse stock split, based on 5,983,670 shares of
our Common Stock outstanding as of January 3, 2006 and without accounting for
fractional shares which will be cancelled and paid for in cash, will be 997,278.
Up to approximately 30,270,000 shares will be reserved for issuance pursuant to
the outstanding options, warrants or Series C Preferred Stock and for future
issuances under the Company's equity incentive plans.

Although the reverse stock split will not affect the rights of stockholders
or any stockholder's proportionate equity interest in MacroChem (subject to the
treatment of fractional shares), the number of authorized shares of Common Stock
will not be reduced. This will increase significantly the ability of the Board
to issue authorized and unissued shares without further stockholder action. The
issuance in the future of such additional authorized shares may have the effect
of diluting the earnings per share and book value per share, as well as the
stock ownership and voting rights, of the currently outstanding shares of Common
Stock. The effective increase in the number of authorized but unissued shares of
Common Stock may be construed as having an anti-takeover effect by permitting
the issuance of shares to purchasers who might oppose a hostile takeover bid or
oppose any efforts to amend or repeal certain provisions of the Company's
certificate of incorporation or bylaws.

The reverse stock split will reduce the number of shares of Common Stock
available for issuance under the Company's 2001 Incentive Plan in proportion to
the one for six exchange ratio. There are also certain outstanding stock options
and warrants to purchase shares of Common Stock and shares of Series C Preferred
Stock which are convertible into shares of Common Stock. Under the terms of the
outstanding stock options and warrants and the Series C Preferred Stock, the
reverse stock split will effect a reduction in the number of shares of Common
Stock issuable upon exercise of such stock options and warrants and issuable
upon conversion of such Series C Preferred Stock in proportion to the one for
six exchange ratio of the reverse stock split and will effect a proportionate
increase in the exercise price of such outstanding stock options and warrants
and the conversion price of the Series C Preferred Stock. None of the rights
currently accruing to holders of our Common Stock, options, warrants or Series C
Preferred Stock would be affected by the reverse stock split.

The reverse stock split will increase the number of stockholders of
MacroChem who own "odd lots" of less than 100 shares of Common Stock. Brokerage
commissions and other costs of transactions in odd lots are generally higher
than the costs of transactions of more than 100 shares of Common Stock.

The Common Stock is currently registered under Section 12(g) of the
Securities Exchange Act of 1934, as amended, and the Company is subject to the
periodic reporting and other requirements of the Exchange Act. The reverse stock
split will not affect the registration of the Common Stock under the Exchange
Act. Following the reverse stock split, the Common Stock will continue to be
quoted on the OTCBB.

EFFECTIVE DATE

The reverse stock split will become effective as of 5:00 p.m. Eastern time
on the date of filing of a certificate of amendment to the Company's certificate
of incorporation with the office of the Secretary of State of the State of
Delaware. Except as explained below with respect to fractional shares, on the
effective date, shares of Common Stock issued and outstanding immediately prior
thereto will be combined and converted, automatically and without any action on
the part of the stockholders, into new shares of Common Stock in accordance with
the one-to-six reverse stock split ratio.

PAYMENT FOR FRACTIONAL SHARES

The Company's transfer agent will act as exchange agent for purposes of
implementing the exchange of stock certificates. Such person is referred to as
the "exchange agent."

No fractional shares of Common Stock will be issued as a result of the
reverse stock split. Instead, stockholders who otherwise would be entitled to
receive fractional shares, upon surrender to the exchange agent of such
certificates representing such fractional shares, will be entitled to receive
cash in an amount equal to the product obtained by multiplying (i) the closing
sales price of the Common Stock on the effective date by (ii) the number of
shares of Common Stock held by such stockholder that would otherwise have been
exchanged for such fractional share interest.

EXCHANGE OF STOCK CERTIFICATES

As soon as practicable after the effective date, stockholders will be
notified that the reverse split has been effected. Holders of pre-reverse split
shares will be asked to surrender to the exchange agent certificates
representing pre-reverse split shares in exchange for certificates representing
post-reverse split shares in accordance with the procedures to be set forth in a
letter of transmittal to be sent by the Company. No new certificates will be
issued to a stockholder until such stockholder has surrendered such
stockholder's outstanding certificate(s) together with the properly completed
and executed letter of transmittal to the exchange agent. Stockholders should
not destroy any stock certificate and should not submit any certificates until
requested to do so.

ACCOUNTING CONSEQUENCES

The par value per share of Common Stock will remain unchanged at $0.01 per
share after the reverse stock split. As a result, on the effective date of the
reverse split, the stated capital on the Company's balance sheet attributable to
the Common Stock will be reduced proportionally, based on the one-to-six
exchange ratio of the reverse stock split, from its present amount, and the
additional paid-in capital account will be credited with the amount by which the
stated capital is reduced. The per share Common Stock net income or loss and net
book value will be increased because there will be fewer shares of Common Stock
outstanding. It is not anticipated that any other accounting consequences would
arise as a result of the reverse stock split.

NO APPRAISAL RIGHTS

Under the Delaware General Corporation Law, the Company's stockholders are
not entitled to dissenter's rights with respect to the amendment to the
Company's certificate of incorporation to effect the reverse split and the
Company will not independently provide the stockholders with any such right.

MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS OF THE REVERSE STOCK SPLIT

The following is a summary of material U.S. federal income tax
considerations of the reverse stock split. It addresses only stockholders who
hold the pre-reverse split shares and post-reverse split shares as capital
assets. It does not purport to be complete and does not address stockholders
subject to special rules, such as financial institutions, tax-exempt
organizations, insurance companies, dealers in securities, mutual funds, foreign
stockholders, stockholders who hold the pre-reverse split shares as part of a
straddle, hedge, constructive sale or conversion transaction, stockholders who
hold the pre-reverse split shares as qualified small business stock within the
meaning of Section 1202 of the Internal Revenue Code of 1986, as amended (the
"Code"), stockholders who are subject to the alternative minimum tax provisions
of the Code, and stockholders who acquired their pre-reverse split shares
pursuant to the exercise of employee stock options or otherwise as compensation.
This summary is based upon current law, which may change, possibly even
retroactively. It does not address tax considerations under state, local,
foreign, and other laws (including other U.S. federal tax laws). Furthermore,
the Company has not obtained a ruling from the Internal Revenue Service or an
opinion of legal or tax counsel with respect to the consequences of the reverse
stock split. EACH STOCKHOLDER IS ADVISED TO CONSULT HIS OR HER TAX ADVISOR AS TO
HIS OR HER OWN SITUATION AND THE PARTICULAR FEDERAL, STATE, LOCAL OR FOREIGN
INCOME OR OTHER TAX CONSEQUENCES OF THE REVERSE STOCK SPLIT.

The reverse stock split is intended to constitute a reorganization within
the meaning of Section 368 of the Code and is not part of a plan to increase
periodically a stockholder's proportionate interest in the assets or earnings
and profits of the Company. Assuming the reverse split qualifies as a
reorganization, a stockholder generally will not recognize gain or loss on the
reverse stock split, except to the extent of cash, if any, received in lieu of a
fractional share interest in the post-reverse split shares. The aggregate tax
basis of the post-reverse split shares received will be equal to the aggregate
tax basis of the pre-reverse split shares exchanged therefor (excluding any
portion of the holder's basis allocated to fractional shares), and the holding
period of the post-reverse split shares received will include the holding period
of the pre-reverse split shares exchanged therefor.

A holder of the pre-reverse split shares who receives cash in lieu of a
fractional share interests in the post-reverse split shares should generally be
treated as having received that cash as a distribution in redemption of the
fractional share. Such holder should consult his or her own tax advisor in
regards to the tax effect of the redemption (i.e., capital gain or dividend
treatment) in light of his or her particular facts and circumstances.

No gain or loss will be recognized by the Company as a result of the
reverse stock split.

REQUIRED CONSENT

The affirmative consent of the holders of a majority of the shares of
the Common Stock, determined assuming conversion of issued and outstanding
Series C Preferred Stock into Common Stock, is required to approve the amendment
to the Company's certificate of incorporation effecting the reverse split. The

Principal Stockholders, who hold a majority of the outstanding Voting Stock,
have consented to the Reverse Stock Split.

BENEFICIAL OWNERSHIP OF VOTING SECURITIES

The following table sets forth, as of January 3, 2006 (except as noted),
information concerning ownership of our common stock by (1) each person known by
us to be the beneficial owner of more than five percent (5%) of our outstanding
Common Stock and Series C Preferred Stock, (2) each of our directors, (3) each
of our executive officers who were serving as executive officers as of December
31, 2005 and (4) all directors and executive officers as a group. Except as
otherwise indicated, the stockholders listed in the table have sole voting and
investment powers with respect to the shares indicated. There were a total of
5,983,670 shares of our Common Stock and 250 shares of our Series C Preferred
Stock outstanding on January 3, 2006.

We have determined the number of shares beneficially owned by each
stockholder under rules promulgated by the SEC. The information is not
necessarily indicative of beneficial ownership for any other purpose. Under
these rules, beneficial ownership includes any shares as to which the individual
or entity has sole or shared voting or investment power and any shares as to
which the individual or entity has the right to acquire beneficial ownership
within 60 days after January 3, 2006 through the exercise of any stock option,
warrant or other right. The inclusion in the following table of those shares,
however, does not constitute an admission that the named stockholder is a direct
or indirect beneficial owner.

NAME AND ADDRESS NUMBER OF SHARES PERCENTAGE
CLASS OF STOCK OF BENEFICIAL OWNER BENEFICIALLY OWNED OF CLASS
____________________________________________________________________________________________________________________
FIVE PERCENT STOCKHOLDERS
Series C Preferred Stock SCO Capital Partners LLC (1).......... 200 80.00%
Series C Preferred Stock Lake End Capital LLC (2).............. 50 20.00%

DIRECTORS AND EXECUTIVE OFFICERS (3)
Series C Preferred Stock Robert J. DeLuccia (3)................ 0 *
Series C Preferred Stock Bernard R. Patriacca (3).............. 0 *
Series C Preferred Stock Melvin A. Snyder (3)(4)............... 0 *
Series C Preferred Stock Thomas C.K. Chan (3)(4)............... 0 *
Series C Preferred Stock Glenn E. Deegan (3)................... 0 *
Series C Preferred Stock Peter G. Martin (3)................... 0 *
Series C Preferred Stock Michael A. Davis (3).................. 0 *
Series C Preferred Stock Paul S. Echenberg (3)................. 0 *
Series C Preferred Stock John L. Zabriskie (3)................. 0 *
Series C Preferred Stock Jeffrey B. Davis (2)(5)............... 50 20.00%
Series C Preferred Stock Howard S. Fischer (5)................. 0 *
Series C Preferred Stock All directors and officers as a
group (11 persons)................ 0 20.00%

FIVE PERCENT STOCKHOLDERS
Common Stock SCO Capital Partners LLC(1)........... 23,714,285 79.85%
Common Stock Galleon Management L.P. (6)........... 518,963 8.62%
Common Stock Arnold H. Snider (7).................. 411,515 6.88%

DIRECTORS AND EXECUTIVE OFFICERS (3)
Common Stock Robert J. DeLuccia (3)(8)............. 160,624 2.63%
Common Stock Bernard R. Patriacca (3)(8)(9)........ 77,190 1.28%
Common Stock Melvin A. Snyder (3)(4)(8)(9)......... 70,369 1.16%
Common Stock Thomas C.K. Chan (3)(4)(8)(9)......... 75,120 1.24%

NAME AND ADDRESS NUMBER OF SHARES PERCENTAGE
CLASS OF STOCK OF BENEFICIAL OWNER BENEFICIALLY OWNED OF CLASS
____________________________________________________________________________________________________________________
Common Stock Glenn E. Deegan (3)(8)(9)............. 43,042 *
Common Stock Peter G. Martin (3)(8)................ 21,753 *
Common Stock Michael A. Davis (3)(8)............... 21,000 *
Common Stock Paul S. Echenberg (3)(8)(10).......... 27,301 *
Common Stock John L. Zabriskie (3)(8)(11).......... 130,492 2.17%
Common Stock Jeffrey B. Davis (2)(5)............... 311,616 4.95%
Common Stock Howard S. Fischer (5)(12)............. 142,857 2.33%
All directors and officers as a
Common Stock group (11 persons) (8)(9)......... 1,081,364 15.76%
<FN>
_______________________
* Less than one percent (1%).
(1) According to a Schedule 13D dated December 23, 2005, filed jointly by SCO
Capital Partners LLC, SCO Securities LLC and Steven H. Rouhandeh, SCO
Capital Partners LLC is the record owner of the securities listed in the
table. Mr. Rouhandeh, as Chairman and sole member of SCO Capital Partners
LLC, has sole dispositive and voting power with respect to all shares
listed in the table. The shares of common stock listed as beneficially
owned by SCO Capital Partners LLC include 12,285,714 shares of common stock
issuable upon the exercise of warrants exerciseable within 60 days and
11,428,571 shares of common stock issuable upon the conversion of Series C
Preferred Stock convertible within 60 days. The address of SCO Capital
Partners LLC is 1285 Avenue of the Americas, 35th Floor, New York, New York
10019.
(2) Lake End Capital LLC is the record owner of the securities listed in the
table. Mr. Jeffrey Davis, as managing member of Lake End Capital LLC, has
sole dispositive and voting power with respect to all shares held of record
by Lake End Capital LLC. The shares of common stock listed as beneficially
owned by Jeffrey Davis include the shares of common stock issuable upon the
conversion of the Series C Preferred Stock held by Lake End Capital LLC and
upon exercise of the warrants held by Lake End Capital LLC within 60 days.
The Series C Preferred Stock and the warrants held by Lake End Capital LLC
are subject to restrictions on their conversion and exercise, respectively,
such that as a result of their conversion or exercise, Lake End Capital
LLC, together with its affiliates, cannot hold more than 4.95% of the
issued and outstanding common stock of the Company. The address of Lake End
Capital LLC is 33 Tall Oaks Drive, Summit, New Jersey 07501.
(3) The address of Mr. DeLuccia, Mr. Patriacca, Mr. Snyder, Dr. Chan, Mr.
Deegan, Mr. Martin, Dr. Davis, Mr. Echenberg and Dr. Zabriskie, is c/o
MacroChem, 110 Hartwell Avenue, Lexington, Massachusetts 02421.
(4) As of November 30, 2005, Mr. Snyder and Mr. Chan are no longer employed by
the Company.
(5) On December 29, 2005, Mr. Jeffrey Davis and Mr. Fischer were appointed to
the Company's board of directors. Mr. Davis and Mr. Fischer were
designated by SCO Capital Partners LLC in accordance with terms and
provisions of the Purchase Agreement and constitute the "SCO Designated
Directors" (as defined in the Purchase Agreement). The address of Mr. Davis
and Mr. Fischer is 1285 Avenue of the Americas, 35th Floor, New York,
New York 10019.
(6) According to a Schedule 13-G/A dated December 31, 2004, filed jointly by
Galleon Management, L.P. ("Galleon"), Raj Rajaratnam, Galleon Management,
L.L.C., Galleon Advisors, L.L.C., Galleon Captains Partners, L.P., Galleon
Captains Offshore, Ltd., Galleon Healthcare Partners, L.P., and Galleon
Healthcare Offshore, Ltd. (collectively, the "Galleon Entities"), Mr.
Rajaratnam, Galleon Management, L.L.C. and Galleon Management, L.P. have
shared dispositive and voting power with respect to all shares listed in
the table, Galleon Advisors, L.L.C. has shared dispositive and voting power
with respect to 71,030 of the shares listed in the table, Galleon Captains
Partners, L.P. has shared dispositive and voting power with respect to
21,916 of the shares listed in the table, Galleon Captains Offshore, Ltd.
has shared dispositive and voting power with respect to 83,555 of the
shares listed in the table, Galleon Healthcare Partners, L.P. has shared
dispositive and voting power with respect to 49,114 of the shares listed in
the table and Galleon Healthcare Offshore, Ltd. has shared dispositive and
voting power with respect to 364,378 of the shares listed in the table. The
shares listed as beneficially owned by Galleon include the following
numbers of shares issuable upon the exercise of warrants exercisable within
60 days: Galleon Captain's Offshore, Ltd.-4,068 shares; Galleon Captain's
Partners, LP-1,017 shares; Galleon Healthcare Offshore, Ltd.-25,285 shares;
and Galleon Healthcare Partners, LP-3,285 shares. The address of the
principal place of business of Galleon Management L.P. is 135 East 57th

Street, 16th Floor, New York, NY 10022.
(7) According to a Schedule 13-G/A dated December 31, 2004, filed jointly by
Arnold H. Snider, Deerfield Capital, L.P. ("Deerfield Capital"), Deerfield
Partners, L.P. ("Deerfield Partners"), Deerfield Management Company, L.P.
("Deerfield Management") and Deerfield International Limited ("Deerfield
International", and collectively with Arnold H. Snider, Deerfield Capital,
Deerfield Partners, Deerfield Management and Deerfield International, the
"Deerfield Entities"), Arnold H. Snider has shared dispositive and voting
power with respect to all shares listed in the table, Deerfield Capital and
Deerfield Partners have shared dispositive and voting power with respect to
198,762 of the shares listed in the table and Deerfield Management and
Deerfield International have shared dispositive and voting power with
respect to 212,753 of the shares listed in the table. The address of the
principal place of business of Deerfield International is c/o Hemisphere
Management (B.V.I.) Limited, Bison Court, Columbus Centre, P.O. Box 3460,
Road Town, Tortola, BVI. The address of the principal place of business of
each of the other entities is 780 Third Avenue, 37th Floor, New York, NY
10017.
(8) Includes the following numbers of shares issuable upon the exercise of
stock options exercisable within 60 days: Mr. Martin-21,429 shares; Dr.
Davis-20,143 shares; Mr. DeLuccia-118,072 shares; Mr. Echenberg-14,286
shares; Dr. Zabriskie-39,405 shares; Mr. Patriacca-66,838 shares; Mr.
Snyder-66,558 shares; Dr. Chan-60,429 shares; and Mr. Deegan-15,714 shares.
(9) Does not include the following numbers of vested shares in our 401(k) Plan
contributed by us to match portions of cash contributions by the following
Plan participants: Mr. Patriacca-3,207 shares; Mr. Snyder- 3,110 shares;
Dr. Chan-3,323 shares; and Mr. Deegan-3,375 shares.
(10) Includes 12,444 shares and warrants held by Eckvest Equity Inc., of which
Mr. Echenberg is the President and sole equity owner.
(11) Includes 99,552 shares and warrants held by Lansing Brown Investments LLC,
of which Dr. Zabriskie and his wife are the managers and sole equity
holders.
(12) Includes 142,857 shares of common stock issuable upon the exercise of a
warrant that is exerciseable within 60 days.
</FN>

PROPOSALS BY SECURITY HOLDERS

No stockholder has requested the Company to include any additional
proposals in this Information Statement.

DELIVERY OF DOCUMENTS TO STOCKHOLDERS SHARING AN ADDRESS

We have adopted a procedure approved by the Securities and Exchange
Commission called "householding." Under this procedure, we will deliver only one
copy of our Information Statement to stockholders to multiple stockholders who
share the same address (if they appear to be members of the same family) unless
one or more of these shareholders notifies us that they wish to continue
receiving individual copies. We believe this procedure provides greater
convenience for our shareholders and saves money by reducing the number of
duplicate documents.

If you and other shareholders of record with whom you share an address
currently receive multiple copies of our Information Statement and wish to
receive only a single copy of future Information Statements, please
contact ADP-ICS, Householding Department, 51 Mercedes Way, Edgewood, NY 11717,
or call toll-free (800) 542-1061. If you participate in householding and wish to
receive additional copies of the current Information Statement, or if you wish
to revoke your consent and receive separate copies of Information Statements,
please contact ADP as described above.

By Order of the Board of Directors,

Lexington, Massachusetts Glenn E. Deegan, Esq.
January ___, 2006 VICE PRESIDENT, GENERAL COUNSEL AND
SECRETARY

APPENDIX A

CERTIFICATE OF AMENDMENT OF
CERTIFICATE OF INCORPORATION OF
MACROCHEM CORPORATION

MacroChem Corporation, a corporation organized and existing under and by
virtue of the General Corporation Law of the State of Delaware (the
"Corporation"), does hereby certify:

FIRST: The name of the Corporation is MacroChem Corporation

SECOND: The Certificate of Incorporation of the Corporation was originally
filed with the Secretary of State of the State of Delaware on May 15, 1992.

THIRD: The Board of Directors of the Corporation, acting in accordance
with the provisions of Sections 141 and 242 of the General Corporation Law of
the State of Delaware, adopted a resolution by written consent setting forth a
proposed amendment to the Corporation's Certificate of Incorporation.

FOURTH: Thereafter, pursuant to a resolution of the Board of Directors,
this Certificate of Amendment was submitted to the stockholders of the
Corporation for approval, and was duly adopted in accordance with the provisions
of Section 242 and Section 228 of the General Corporation Law of the State of
Delaware. The total number of outstanding shares entitled to vote or consent to
this Certificate of Amendment was [________] shares of Common Stock and [____]
shares of Series C Cumulative Convertible Preferred Stock (the "SERIES C
STOCK"), which Series C Stock is convertible, in the aggregate, into [_____]
shares of Common Stock and votes on an as-if-converted into Common Stock basis
(subject to the Beneficial Ownership Cap (as defined in the Certificate of
Designations, Rights and Preferences of the Series C Stock)) together with the
Common Stock. A majority of the shares of Common Stock represented by the
outstanding shares of Common Stock and the outstanding shares of Series C Stock
(on an as-if-converted to Common Stock basis), voting together as a single
class, consented to this Certificate of Amendment of the Certificate of
Incorporation. The consent required was a majority of the shares of Common Stock
represented by the outstanding shares of Common Stock and the outstanding shares
of Series C Stock (on an as-if-converted to Common Stock basis), voting together
as a single class.

FIFTH: Accordingly, upon the effectiveness hereof, paragraph 4 of the
Corporation's Certificate of Incorporation shall be amended and restated to read
in its entirety as follows:

"The total number of shares of stock which the corporation shall have authority
to issue is one hundred-six million (106,000,000) shares, 100,000,000 of which
shall be Common Stock, of the par value of One Cent ($.01) per share; 6,000,000
of which shall be Preferred Stock, of the par value of One Cent ($.01) per
share, 500,000 of which shall be designated as "Series A Convertible Preferred
Stock", of the par value of One Cent ($.01) per share, and 1,500 of which shall
be designated as "Series C Cumulative Convertible Preferred Stock", of the par

value of One Cent ($.01) per share, amounting in the aggregate to One Million
Sixty Thousand and 00/100 Dollars ($1,060,000.00). Effective as of 5:00 p.m.,
Eastern time, on the date this Certificate of Amendment of the Certificate of
Incorporation is filed with the Secretary of State of the State of Delaware,
each six (6) shares of the Corporation's Common Stock, par value $.01 per share,
issued and outstanding shall, automatically and without any action on the part
of the respective holders thereof, be combined and converted into one (1) share
of Common Stock, par value $.01 per share, of the Corporation. No fractional
shares shall be issued and, in lieu thereof, any holder of less than one share
of Common Stock shall be entitled to receive cash for such holder's fractional
share based upon the closing sales price of the Corporation's Common Stock as
reported on the over-the-counter market as of the date this Certificate of
Amendment is filed with the Secretary of State of the State of Delaware.

Additional designations and powers, preferences and rights and qualifications,
limitations or restrictions thereof of the shares of stock shall be determined
by the Board of Directors of the Corporation from time to time."

IN WITNESS WHEREOF, MacroChem Corporation has caused this Certificate of
Amendment to be signed by its President and Chief Executive Officer on this
____day of _________, 2006.

MACROCHEM CORPORATION
By:

_____________________________________
Robert J. DeLuccia
PRESIDENT AND CHIEF EXECUTIVE OFFICER
VICE CHAIRMAN OF THE BOARD